Finance

Lists
STOK:NASDAQ
Stoke Therapeutics Inc
$26.63
-0.19%
(-0.050) 1D
$26.63
0.00% (0.00)
After hours
Closed: Nov 16, 4:00:00 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for STOK...
Open
$26.68
High
$27.50
Low
$26.37
Mkt. cap
1.74B
Avg. vol.
1.18M
Volume
581.60K
52-wk high
$40.22
52-wk low
$22.05
EPS
-$3.78
Beta
1.36
Shares outstanding
65.41M
No. of employees
170
Open
$26.68
High
$27.50
Low
$26.37
Mkt. cap
1.74B
Avg. vol.
1.18M
Volume
581.60K
52-wk high
$40.22
52-wk low
$22.05
EPS
-$3.78
Beta
1.36
Shares outstanding
65.41M
No. of employees
170
News stories
From web sources and news partners
About Stoke Therapeutics Inc
CEO-
Employees170
Founded2014
HeadquartersBedford, Massachusetts, United States
SectorHealth Care
IndustryBiotechnology
Analyst ratings
Based on 8 analysts giving stock ratings to STOK in the past 3 months
Strong buy
Buy
8
Hold
0
Sell
0
12-month forecast
Based on 8 Wall Street analysts offering 12 month price targets for STOK in the last 3 months.
Highest
Current $26.63
$60.00 (+125.31%)
Average
$48.75 (+83.06%)
Lowest
$39.00 (+46.45%)
Analyst
Recommendation
Action
Price target
Projected
Date
Ananda Ghosh
H.C. Wainwright
Buy
Maintained
$50.00
+87.8%
11/02/2026
Sumant Kulkarni
Canaccord Genuity
Buy
Reiterated
$58.00
+117.8%
11/02/2026
Thomas Shrader
BTIG
Buy
Maintained
$39.00
+46.5%
11/01/2026
Unknown Analyst
Wedbush
Buy
Maintained
$40.00
+50.2%
10/30/2026
Kevin Strang
Goldman Sachs
Buy
Maintained
$43.00
+61.5%
10/30/2026
Unknown Analyst
Guggenheim
Buy
Reiterated
$60.00
+125.3%
10/29/2026
Yaron Werber
TD Cowen
Buy
Reiterated
$60.00
+125.3%
10/13/2026
Jessica Fye
J.P. Morgan
Buy
Initiated
$40.00
+50.2%
08/21/2026
Rudy Li
Wolfe Research
Buy
Maintained
$40.00
+50.2%
08/03/2026
Joseph Stringer
Needham
Buy
Maintained
$40.00
+50.2%
08/04/2026
Keay Nakae
Chardan Capital
Buy
Maintained
$35.00
+31.4%
08/03/2026
Unknown Analyst
Jefferies
Buy
Maintained
$48.00
+80.2%
07/06/2026
Marc Goodman
Leerink Partners
Buy
Maintained
-
-
06/02/2026
Laura Chico
Wedbush
Buy
Maintained
$38.00
+42.7%
05/08/2026
Yatin Suneja
Guggenheim
Buy
Maintained
$60.00
+125.3%
05/07/2026
Last report
Oct 29, 2026
Fiscal period
Q3 2026
-$1.08 / -$0.91
-18.12%miss
Revenue / Est. (USD)
11.26M / 8.18M
+37.51%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
1.40M
6.23M
9.32M
11.26M
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
41.70M
39.67M
49.50M
59.83M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
21.15M
19.97M
25.25M
28.74M
Operating expense
62.84M
59.65M
74.75M
88.57M
Total operating expenses
62.84M
59.65M
74.75M
88.57M
Operating income
-61.44M
-53.42M
-65.43M
-77.32M
Other non operating income
-110.00K
18.00K
308.00K
6.00K
EBT including unusual items
-57.93M
-50.00M
-61.62M
-73.64M
EBT excluding unusual items
-57.93M
-50.00M
-61.62M
-73.64M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-57.93M
-50.00M
-61.62M
-73.64M
Net profit margin
-4,132.24%
-802.75%
-660.78%
-654.32%
Earnings per share
-0.97
-0.79
-0.93
-1.08
Interest and investment income
3.62M
3.42M
3.52M
3.68M
Interest expense
-3.00K
-23.00K
-17.00K
-20.00K
Net interest expenses
3.62M
3.40M
3.50M
3.66M
Depreciation and amortization charges
-
-
-
-
EBITDA
-61.03M
-52.98M
-64.97M
-76.86M
Gain or loss from assets sale
153.00K
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google apps